Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gliknik Inc. holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this portfolio, which indicates a focused and singular point of active prosecution. This level of activity suggests that the company is currently prioritizing a specific technological advancement or a single patent application.
The examination of this portfolio is handled by 1 distinct examiner. This examiner works within 1 distinct art unit, which suggests that the company's Biotechnology & Pharmaceuticals innovations are currently being reviewed within a specific technical specialty. DAHLE, CHUN WU is the busiest examiner for the portfolio. This examiner is currently overseeing the 1 pending office action on record.
With a busiest examiner pending count of 1, the company's entire active prosecution is concentrated under a single individual. This concentration allows for a highly specific prosecution strategy tailored to the feedback of 1 distinct examiner. The company's progress in the Biotechnology & Pharmaceuticals field is currently tied to the resolution of this 1 pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18162308 | FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED FC RECEPTOR BINDING | DAHLE, CHUN WU | 8d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18162308 | FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED FC RECEPTOR BINDING | DAHLE, CHUN WU | 1641 | §103 | Non-Final OA | 8d | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial